BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price, Forecast & Analysis
Europe - FRA:BSX - US1011371077 - Common Stock
BSX.DE Key Statistics, Chart & Performance
The current stock price of BSX.DE is 84.4 EUR. In the past month the price increased by 2.59%. In the past year, price increased by 1.16%.
BSX.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 18.16 | 111.13B | ||
| 1SHL.MI | SIEMENS HEALTHINEERS AG | 18.38 | 49.34B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 21.73 | 46.58B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.18 | 22.44B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.23 | 22.50B | ||
| BIM.PA | BIOMERIEUX | 27.38 | 12.51B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 24.87 | 3.80B | ||
| DIA.MI | DIASORIN SPA | 16.95 | 3.29B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.54 | 1.28B | ||
| DRW8.DE | DRAEGERWERK AG | 9.58 | 1.16B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 26.17 | 980.75M | ||
| ELN.MI | EL.EN. SPA | 18.28 | 938.69M |
Related stock screener links
About BSX.DE
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 53000
Phone: 15086834000
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the stock price of BOSTON SCIENTIFIC CORP today?
The current stock price of BSX.DE is 84.4 EUR. The price decreased by -4.52% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX.DE does not pay a dividend.
How is the ChartMill rating for BOSTON SCIENTIFIC CORP?
BSX.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is BOSTON SCIENTIFIC CORP (BSX.DE) stock traded?
BSX.DE stock is listed on the Deutsche Boerse Ag exchange.
What do analysts say about BOSTON SCIENTIFIC CORP (BSX.DE) stock?
41 analysts have analysed BSX.DE and the average price target is 110.54 EUR. This implies a price increase of 30.97% is expected in the next year compared to the current price of 84.4.
Is BOSTON SCIENTIFIC CORP (BSX.DE) expected to grow?
The Revenue of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 20.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
BSX.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BSX.DE. When comparing the yearly performance of all stocks, BSX.DE is a bad performer in the overall market: 69.05% of all stocks are doing better.
BSX.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. BSX.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
BSX.DE Financial Highlights
Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.55. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
BSX.DE Forecast & Estimates
41 analysts have analysed BSX.DE and the average price target is 110.54 EUR. This implies a price increase of 30.97% is expected in the next year compared to the current price of 84.4.
For the next year, analysts expect an EPS growth of 22.11% and a revenue growth 20.9% for BSX.DE